Boothbay Fund Management LLC Takes $1 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Boothbay Fund Management LLC acquired a new stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 58,944 shares of the biotechnology company's stock, valued at approximately $1,000,000. Boothbay Fund Management LLC owned 0.22% of Arcturus Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Arcturus Therapeutics by 6.8% during the fourth quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company's stock worth $28,587,000 after acquiring an additional 107,635 shares in the last quarter. Geode Capital Management LLC boosted its position in Arcturus Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company's stock valued at $9,421,000 after purchasing an additional 3,186 shares during the last quarter. Empire Life Investments Inc. raised its stake in shares of Arcturus Therapeutics by 85.5% during the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company's stock worth $4,742,000 after purchasing an additional 128,771 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Arcturus Therapeutics by 5.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 207,802 shares of the biotechnology company's stock valued at $3,526,000 after acquiring an additional 10,180 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Arcturus Therapeutics by 54.6% during the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company's stock worth $2,412,000 after purchasing an additional 36,714 shares during the period. Institutional investors and hedge funds own 94.54% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on ARCT shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Wells Fargo & Company dropped their price objective on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Canaccord Genuity Group cut their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a report on Monday, March 10th. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. Finally, BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the stock a "buy" rating in a research note on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $59.20.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock traded down $0.75 during mid-day trading on Monday, hitting $12.09. 85,354 shares of the stock were exchanged, compared to its average volume of 448,228. The company has a 50-day simple moving average of $12.35 and a 200 day simple moving average of $15.74. Arcturus Therapeutics Holdings Inc. has a 12 month low of $8.04 and a 12 month high of $45.00. The company has a market capitalization of $327.76 million, a P/E ratio of -5.47 and a beta of 3.41.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $22.77 million for the quarter, compared to analysts' expectations of $44.64 million. Analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.